title: Future directions in mucormycosis research.
abstract: Mucormycosis has emerged as an important opportunistic infection, especially in severely immunosuppressed hosts. The evolving epidemiology, immunopathogenesis, molecular virulence studies, early diagnosis, and pitfalls in designing clinical studies of mucormycosis are discussed in this article.
authors.affiliation: Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. dkontoyi@mdanderson.org
authors.forename: Dimitrios P
authors.initials: DP
authors.lastname: Kontoyiannis
authors.forename: Russell E
authors.initials: RE
authors.lastname: Lewis
authors.forename: Oliver
authors.initials: O
authors.lastname: Lortholary
authors.forename: Oliver
authors.initials: O
authors.lastname: Lotholary
authors.forename: Brad
authors.initials: B
authors.lastname: Spellberg
authors.forename: Georgios
authors.initials: G
authors.lastname: Petrikkos
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Roilides
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Roillides
authors.forename: Ashraf
authors.initials: A
authors.lastname: Ibrahim
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Walsh
mesh_terms: D000935:Antifungal Agents / Q000494:pharmacology; D001230:Aspergillus / Q000235:genetics / Q000276:immunology / Q000472:pathogenicity*; D035843:Biomedical Research; D042241:Early Diagnosis; D016681:Genome, Fungal; D006801:Humans; D016867:Immunocompromised Host; D009091:Mucormycosis / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology* / Q000473:pathology; D011743:Pyrimidines / Q000494:pharmacology; D012233:Rhizopus / Q000235:genetics / Q000276:immunology / Q000472:pathogenicity*; D012307:Risk Factors; D014230:Triazoles / Q000494:pharmacology; D065819:Voriconazole
chemical_list: D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole